LAMAs showed no clear difference in adverse events after tiotropium 5.0 µg compared with placebo (high certainty).
LAMAs showed no clear difference in pulmonary exacerbations: participants reporting ≥1 pulmonary… compared with placebo (moderate certainty).
It is very uncertain whether aclidinium bromide changes hospital admissions due to exacerbations compared with tiotropium (very low certainty).
It is very uncertain whether aclidinium bromide changes non‐fatal serious adverse events compared with tiotropium (very low certainty).
It is very uncertain whether aclidinium bromide changes exacerbations requiring steroids, antibiotics or both compared with tiotropium (very low certainty).